Amicus Therapeutics, Inc. (FOLD) Tops Q1 EPS by 1c; Guides In-line
Amicus Therapeutics, Inc. (NASDAQ: FOLD) reported Q1 EPS of ($0.35), $0.01 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.52 million.
Amicus continues to expect full-year 2012 operating expenses will total between $37 million to $43 million (Consensus is $40.26 mln), net of anticipated cost sharing and milestones related to the GSK collaboration. Amicus and GSK equally shared development costs for migalastat HCl (monotherapy and co-administration) in 2011, and GlaxSmithKline (NYSE: GSK) is responsible for 75% of these costs in 2012 and beyond, subject to annual and aggregate caps. Amicus is also eligible to receive up to a total of $170 million in development, regulatory and commercial milestones as part of the Fabry collaboration with GSK.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.
Amicus continues to expect full-year 2012 operating expenses will total between $37 million to $43 million (Consensus is $40.26 mln), net of anticipated cost sharing and milestones related to the GSK collaboration. Amicus and GSK equally shared development costs for migalastat HCl (monotherapy and co-administration) in 2011, and GlaxSmithKline (NYSE: GSK) is responsible for 75% of these costs in 2012 and beyond, subject to annual and aggregate caps. Amicus is also eligible to receive up to a total of $170 million in development, regulatory and commercial milestones as part of the Fabry collaboration with GSK.
For earnings history and earnings-related data on Amicus Therapeutics, Inc. (FOLD) click here.